upgrade to Tier 1 to access blurred content, display up to 300 records, and unlimited CSV download
Data last updated 2024-04-28 04:05:40 -0500 US CDT
Insider Sentiment
| Company Name | Sector | Industry | Shares Outstanding(Mil) | 52-week High/Low | Period | Acq/Dsp Transaction Countb | Ids/Sec/Mkt Quantc | Acq/Dsp Shares Amountb | Acq/Dsp PctSOd |
|---|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics, Inc. | Health Care | Pharmaceuticals | 93.55 |
55.3
159.9
128.8
|
3-month |
0 / 6
|
|
0 / 24096
|
0.0 / 0.0 |
| 6-month |
3 / 6
|
|
75225 / 24096
|
0.1 / 0.0 |
Data last updated 2024-04-27 07:55:23 -0500 US CDT
Major Shareholders
| Shareholder | Relation | Report Date | Holding Pct | Sharesa | Shares(Previous Report Date)a | Transactions (3 month)b | Transactions (6 month)b |
|---|---|---|---|---|---|---|---|
| Barry Richard | Director | 2024-03-05 | 3.4% | 3181688 (3.3%, 3.3%) | 3079842 (2023-11-06) |
C: 2 / 0
S: 50000 / 0 P: 78.81 / NA |
|
| Ingram Douglas S | President & CEO | 2023-11-06 | 0.4% | 390307 (6.9%, NA%) | 365082 (2021-11-17) |
C: 1 / 0
S: 25225 / 0 P: 79.36 / NA |
|
| Chambers Michael Andrew | Director | 2024-03-05 | 0.3% | 255273 (0.7%, 0.7%) | 253427 (2023-08-15) | ||
| Behrens M Kathleen | Director | 2024-03-05 | 0.2% | 186839 (1.0%, 1.0%) | 184993 (2023-11-06) | ||
| Kaye Edward M. Md | Director | 2017-08-07 | 0.1% | 71229 (35.7%, NA%) | 52471 (2017-07-21) | ||
| Rodino Klapac Louise | Head of R&D, CSO | 2024-03-11 | 0.1% | 68073 (-1.9%, 3.5%) | 69494 (2024-03-06) | ||
| Chase Anthony R | Director | 2015-03-03 | 0.1% | 67194 (1.5%, NA%) | 66194 (2014-08-14) | ||
| Price Ben Gil | Director | 2016-03-16 | 0.0% | 42830 (11.7%, NA%) | 38330 (2016-03-02) | ||
| Estepan Ian Michael | Chief Financial Officer | 2024-03-11 | 0.0% | 36164 (-4.0%, NA%) | 37725 (2024-03-06) |
C: 0 / 1
S: 0 / 1200 P: NA / 128.3 |
C: 0 / 1
S: 0 / 1200 P: NA / 128.3 |
| Mahatme Sandesh | EVP, CFO & CBO | 2020-07-09 | 0.0% | 32272 (-33.9%, NA%) | 48891 (2020-02-28) | ||
| Brown Ryan Edward | EVP, General Counsel | 2024-03-11 | 0.0% | 28688 (-4.6%, 2.1%) | 30093 (2024-03-06) |
C: 0 / 1
S: 0 / 2000 P: NA / 125.34 |
C: 0 / 1
S: 0 / 2000 P: NA / 125.34 |
| Arif Bilal | Chief Tech Ops Officer | 2024-03-11 | 0.0% | 25222 (-3.6%, 10.2%) | 26200 (2024-03-06) |
C: 0 / 1
S: 0 / 2000 P: NA / 128.84 |
C: 0 / 1
S: 0 / 2000 P: NA / 128.84 |
| Wigzell Hans Lennart Rudolf | Director | 2024-03-11 | 0.0% | 22840 (0.0%, 8.8%) | 22840 (2024-03-05) |
C: 0 / 1
S: 0 / 15000 P: NA / 123.25 |
C: 0 / 1
S: 0 / 15000 P: NA / 123.25 |
a Total of direct and indirect accounts with percentage change comparing with (previous report, 3 months ago). The latter is NA when no change was found in the last 3 months.
Notice: Shares amount and percentage change 1) do not reflect intraday conversion and execution of derivative securities. 2) may subject to correction on amendment filing.
b Vital&Spontaneous transactions of the past 3 and 6 months, respectively. For acquisitions, code P (open market purchase), L (small acquisition), and I (at discretion of broker) are counted. For dispositions, code S (open market sell), D (sell back to issuer) and I (at discretion of broker) are counted. "C:" count of number of transactions. "S:" shares amount involved in corrresponding transactions. "P:" average per share price of the transactions (for reference only). Horizontal bar chart denotes shares amount of acquisitions and dispositions. Black thin bar is fixed size ruler for easy comparison between reporters.
c Quantile value of transaction count in b among industry peers, sector peers, and the market, respectively.
d Percentage of transaction shares amount to shares outstanding.
Notice: red exclamation mark (!) represents the reporter has Form 4 amendment filings in the latest three reports.
Non-derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Non-derivative Transactions Table
CSV download
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
|
Tips: type "code_p" to show transactions with code "P".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-11 | 2024-03-08 | 2024-03-08 | 4 | Wigzell Hans Lennart Rudolf | DIRECTOR | dsp | 15000.0 | 39.64 | 1.6 | 123.25 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code S | 22840.0
|
93.55 (SRPT) |
| 2024-03-11 | 2024-03-08 | 2024-03-08 | 4 | Wigzell Hans Lennart Rudolf | DIRECTOR | acq | 15000.0 | 39.64 | 1.6 | 13.9 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code M | 37840.0 | 93.55 (SRPT) |
| 2024-03-11 | 2024-03-11 | 2024-03-11 | 4 | Boor Kathryn Jean | DIRECTOR | dsp | 761.0 | 9.19 | 0.08 | 122.93 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code S | 7516.0 | 93.55 (SRPT) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 to 2024-03-08 | 4 | Arif Bilal | CHIEF TECH OPS OFFICER | dsp | 978.0 | 3.73 | 0.1 | 121.77 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F | 25222.0
|
93.55 (SRPT) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 to 2024-03-08 | 4 | Estepan Ian Michael | CHIEF FINANCIAL OFFICER | dsp | 1561.0 | 4.14 | 0.17 | 122.25 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F | 36164.0
|
93.55 (SRPT) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 to 2024-03-08 | 4 | Brown Ryan Edward | EVP, GENERAL COUNSEL | dsp | 1405.0 | 4.67 | 0.15 | 122.19 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F | 28688.0
|
93.55 (SRPT) |
| 2024-03-11 | 2024-03-07 | 2024-03-07 to 2024-03-08 | 4 | Rodino Klapac Louise | HEAD OF R&D, CSO | dsp | 1421.0 | 2.04 | 0.15 | 122.19 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F | 68073.0
|
93.55 (SRPT) |
| 2024-03-06 | 2024-03-04 | 2024-03-04 | 4 | Arif Bilal | CHIEF TECH OPS OFFICER | dsp | 522.0 | 1.95 | 0.06 | 125.32 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F | 26200.0
|
93.55 (SRPT) |
| 2024-03-06 | 2024-03-04 | 2024-03-04 | 4 | Rodino Klapac Louise | HEAD OF R&D, CSO | dsp | 1728.0 | 2.43 | 0.18 | 125.32 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F | 69494.0 | 93.55 (SRPT) |
| 2024-03-06 | 2024-03-04 | 2024-03-04 | 4 | Estepan Ian Michael | CHIEF FINANCIAL OFFICER | dsp | 1389.0 | 3.55 | 0.15 | 125.32 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F | 37725.0 | 93.55 (SRPT) |
| 2024-03-06 | 2024-03-04 | 2024-03-04 | 4 | Brown Ryan Edward | EVP, GENERAL COUNSEL | dsp | 1734.0 | 5.45 | 0.19 | 125.32 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F | 30093.0 | 93.55 (SRPT) |
| 2024-03-06 | 2024-03-05 | 2024-03-05 | 4 | Mayo Stephen | DIRECTOR | dsp | 3135.0 | 32.13 | 0.34 | 122.96 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code S | 6621.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Estepan Ian Michael | CHIEF FINANCIAL OFFICER | acq | 6000.0 | 14.88 | 0.64 | 0.0 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code A | 40314.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Estepan Ian Michael | CHIEF FINANCIAL OFFICER | dsp | 1565.0 | 3.85 | 0.17 | 127.81 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F S | 39114.0
|
93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Arif Bilal | CHIEF TECH OPS OFFICER | acq | 6000.0 | 20.81 | 0.64 | 0.0 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code A | 28836.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Arif Bilal | CHIEF TECH OPS OFFICER | dsp | 2365.0 | 8.13 | 0.25 | 128.43 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F S | 26722.0
|
93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Rodino Klapac Louise | HEAD OF R&D, CSO | dsp | 778.0 | 1.18 | 0.08 | 126.19 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F | 65222.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Rodino Klapac Louise | HEAD OF R&D, CSO | acq | 6000.0 | 8.42 | 0.64 | 0.0 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code A | 71222.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Brown Ryan Edward | EVP, GENERAL COUNSEL | dsp | 2269.0 | 6.65 | 0.24 | 125.44 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code F S | 31827.0
|
93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Brown Ryan Edward | EVP, GENERAL COUNSEL | acq | 6000.0 | 17.74 | 0.64 | 0.0 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code A | 33827.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Chambers Michael Andrew | DIRECTOR | acq | 1846.0 | 22.3 | 0.2 | 0.0 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code A | 8277.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 4 | Chambers Michael Andrew | DIRECTOR | holding | 246996.0 | 0 | 26.4 | 0.0 | By Revocable Trust | Common Stock | SAREPTA THERAPEUTICS, INC. | NA | 93.55 (SRPT) | ||
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Mayo Stephen | DIRECTOR | acq | 1846.0 | 18.92 | 0.2 | 0.0 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code A | 9756.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Barry Richard | DIRECTOR | acq | 1846.0 | 0.06 | 0.2 | 0.0 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code A | 2931688.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 4 | Barry Richard | DIRECTOR | holding | 10000.0 | 0 | 1.07 | 0.0 | By Llc | Common Stock | SAREPTA THERAPEUTICS, INC. | NA | 93.55 (SRPT) | ||
| 2024-03-05 | 2024-03-01 | 4 | Barry Richard | DIRECTOR | holding | 240000.0 | 0 | 25.66 | 0.0 | By Trust | Common Stock | SAREPTA THERAPEUTICS, INC. | NA | 93.55 (SRPT) | ||
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Boor Kathryn Jean | DIRECTOR | acq | 1846.0 | 22.3 | 0.2 | 0.0 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code A | 8277.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Nicaise Claude | DIRECTOR | acq | 1846.0 | 10.16 | 0.2 | 0.0 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code A | 18174.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Behrens M Kathleen | DIRECTOR | acq | 1846.0 | 1.04 | 0.2 | 0.0 | Direct | Common Stock | SAREPTA THERAPEUTICS, INC. | code A | 176839.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 4 | Behrens M Kathleen | DIRECTOR | holding | 10000.0 | 0 | 1.07 | 0.0 | By Trust | Common Stock | SAREPTA THERAPEUTICS, INC. | NA | 93.55 (SRPT) |
Derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Derivative Transactions Table
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-11 | 2024-03-08 | 2024-03-08 | 4 | Wigzell Hans Lennart Rudolf | DIRECTOR | dsp | 15000.0 | 100.0 | 1.6 | 13.9 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code M | 0.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Estepan Ian Michael | CHIEF FINANCIAL OFFICER | dsp | 12500.0 | 50.0 | 1.34 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code A | 12500.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Arif Bilal | CHIEF TECH OPS OFFICER | dsp | 12500.0 | 50.0 | 1.34 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code A | 12500.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Rodino Klapac Louise | HEAD OF R&D, CSO | acq | 12500.0 | 100.0 | 1.34 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code A | 12500.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Brown Ryan Edward | EVP, GENERAL COUNSEL | dsp | 12500.0 | 50.0 | 1.34 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code A | 12500.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Chambers Michael Andrew | DIRECTOR | acq | 3679.0 | 100.0 | 0.39 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code A | 3679.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Mayo Stephen | DIRECTOR | acq | 3679.0 | 100.0 | 0.39 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code A | 3679.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Barry Richard | DIRECTOR | acq | 3679.0 | 100.0 | 0.39 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code A | 3679.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Boor Kathryn Jean | DIRECTOR | acq | 3679.0 | 100.0 | 0.39 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code A | 3679.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Nicaise Claude | DIRECTOR | acq | 3679.0 | 100.0 | 0.39 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code A | 3679.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Behrens M Kathleen | DIRECTOR | acq | 3679.0 | 100.0 | 0.39 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code A | 3679.0 | 93.55 (SRPT) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Wigzell Hans Lennart Rudolf | DIRECTOR | dsp | 3679.0 | 50.0 | 0.39 | 128.67 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code M | 3679.0 | 93.55 (SRPT) |
| 2023-11-06 | 2023-11-03 | 2023-11-03 | 4 | Behrens M Kathleen | DIRECTOR | dsp | 15000.0 | 100.0 | 1.6 | 29.03 | Direct | Stock Option (Right To Buy) | SAREPTA THERAPEUTICS, INC. | code M | 0.0 | 93.55 (SRPT) |
Form 3 CSV download
| Filing Date | Date requiring statement | Form Type | Reporter | Relation | Amounta | ‱(SO)c | Avg Excercisable Prcd | Account | Type | Full Name | Shares Outstanding (Million)e |
|---|
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to 30 records per table for current tier. (Access Guide)